Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entrectinib phase 2 basket study in advanced solid tumors with NTRK, ROS1, or ALK rearrangements
NL-OMON53017Phase 2Recruiting
- Sponsor
- Roche
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of entrectinib in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and 4 more, sponsored by Roche. Primary endpoint: Objective Response Rate. Started Mar 2017; status: recruiting.
02
Drugs
entrectinib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)colorectal cancer (CRC)salivary gland cancer (SGC)papillary thyroid cancer (PTC)
Beyond the preview
Go deeper on NL-OMON53017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53017.